Reader response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

Neurology. 2020 Mar 31;94(13):593-594. doi: 10.1212/WNL.0000000000009184.
No abstract available

Publication types

  • Comment

MeSH terms

  • Alzheimer Disease*
  • Anti-Inflammatory Agents, Non-Steroidal
  • Asymptomatic Diseases
  • Humans
  • Naproxen*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Naproxen